WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 315361
Description: Doxercalciferol, also known as 1-hydroxy Vitamin D2, is a synthetic analog of vitamin D with potential antineoplastic activity. In the liver, doxercalciferol is converted to its biologically active vitamin D metabolites, which control the intestinal absorption of dietary calcium, the tubular reabsorption of calcium by the kidney and, in conjunction with parathyroid hormone (PTH), the mobilization of calcium from the skeleton. Through interaction with specific receptor proteins in target tissues, these vitamin D metabolites act directly on osteoblasts to stimulate skeletal growth, and on the parathyroid glands to suppress PTH synthesis and secretion.
MedKoo Cat#: 315361
Chemical Formula: C28H44O2
Exact Mass: 412.33413
Molecular Weight: 412.65
Elemental Analysis: C, 81.50; H, 10.75; O, 7.75
Synonym: Doxercalciferol. 1-hydroxy Vitamin D2; Hectorol; 1-Hydroxyergocalciferol; TSA 840.
IUPAC/Chemical Name: (1S,3R,Z)-5-((E)-2-((1S,3aR,7aS)-1-((2S,5S,E)-5,6-dimethylhept-3-en-2-yl)-7a-methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol.
InChi Key: HKXBNHCUPKIYDM-UHICYICISA-N
InChi Code: InChI=1S/C28H44O2/c1-18(2)19(3)9-10-20(4)25-13-14-26-22(8-7-15-28(25,26)6)11-12-23-16-24(29)17-27(30)21(23)5/h9-12,18-20,24-27,29-30H,5,7-8,13-17H2,1-4,6H3/b10-9+,22-11+,23-12-/t19-,20+,24+,25+,26-,27-,28+/m1/s1
SMILES Code: O[C@@H]1C[C@@H](O)C(/C(C1)=C\C=C2[C@@]3([H])CC[C@@H]([C@H](/C=C/[C@@H](C)C(C)C)C)[C@]3(C)CCC\2)=C
Appearance: White to yellow/brown solid powder.
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO.
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 412.65 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Wang XX, Jiang T, Shen Y, Santamaria H, Solis N, Arbeeny CM, Levi M. The Vitamin D Receptor Agonist Doxercalciferol Modulates Dietary Fat Induced Renal Disease and Renal Lipid Metabolism. Am J Physiol Renal Physiol. 2011 Jan 5. [Epub ahead of print] PubMed PMID: 21209008.
2: Ritter CS, Brown AJ. Direct Suppression of PTH Gene Expression by the Vitamin D Prohormones Doxercalciferol and Calcidiol Requires the Vitamin D Receptor. J Mol Endocrinol. 2010 Dec 17. [Epub ahead of print] PubMed PMID: 21169421.
3: Ray K. Doxercalciferol is as effective as calcitriol for the treatment of secondary hyperparathyroidism in CKD. Nat Rev Nephrol. 2010 Dec;6(12):692. PubMed PMID: 21155068.
4: Chow EC, Sondervan M, Jin C, Groothuis GM, Pang KS. Comparative effects of doxercalciferol (1α-hydroxyvitamin D(2)) versus calcitriol (1α,25-dihydroxyvitamin D(3)) on the expression of transporters and enzymes in the rat in vivo. J Pharm Sci. 2010 Oct 21. [Epub ahead of print] PubMed PMID: 20967888.
5: Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, JÃ¼ppner H, Salusky IB. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int. 2011 Jan;79(1):112-9. Epub 2010 Sep 22. PubMed PMID: 20861820.
6: Wu-Wong JR, Nakane M, Gagne GD, Brooks KA, Noonan WT. Comparison of the pharmacological effects of paricalcitol and doxercalciferol on the factors involved in mineral homeostasis. Int J Endocrinol. 2010;2010:621687. Epub 2010 Mar 2. PubMed PMID: 20204178; PubMed Central PMCID: PMC2831199.
7: Moe SM, Saifullah A, LaClair RE, Usman SA, Yu Z. A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic kidney disease. Clin J Am Soc Nephrol. 2010 Feb;5(2):299-306. Epub 2010 Jan 7. PubMed PMID: 20056760; PubMed Central PMCID: PMC2827596.
8: Kubodera N. A new look at the most successful prodrugs for active vitamin D (D hormone): alfacalcidol and doxercalciferol. Molecules. 2009 Sep 29;14(10):3869-80. Review. PubMed PMID: 19924035.
9: Zhang Y, Deb DK, Kong J, Ning G, Wang Y, Li G, Chen Y, Zhang Z, Strugnell S, Sabbagh Y, Arbeeny C, Li YC. Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol. 2009 Sep;297(3):F791-801. Epub 2009 Jun 17. PubMed PMID: 19535571; PubMed Central PMCID: PMC2739712.
10: Fadem SZ, Al-Saghir F, Zollner G, Swan S. Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - a dose equivalency and titration study. Clin Nephrol. 2008 Oct;70(4):319-24. PubMed PMID: 18826857.